PT-141
Melanocortin receptor agonist for sexual function and libido research.
1 mg as-needed (1×/week avg)
Key Benefits
acts on hypothalamic melanocortin receptors, not vascular system
bremelanotide approved for HSDD in women
demonstrated in both male and female research subjects
effects within 45–60 minutes of administration
Recommended Injection Sites
Optimal injection locations for PT-141 based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
Preferred SubQ site for rapid absorption.
Good alternative.
Rotate sites each use.
- IV administration
- Intramuscular injection
Active Signaling Pathway
Recommended Stacks
PT-141 is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Hormonal Vitality Stack
HPG axis activation and melanocortin optimization for vitality and libido research.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 10mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, triggering dopaminergic pathways associated with sexual motivation and arousal. This central mechanism is independent of vascular effects, making it effective in subjects where PDE5 inhibitors fail.
Clinical Context
PT-141 is the only FDA-approved peptide for sexual dysfunction that works centrally. Its mechanism through melanocortin receptors makes it complementary to vascular approaches.
Research Highlights
- FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women
- Demonstrated significant improvement in sexual desire scores in Phase 3 trials
- Effective in both male and female subjects via central CNS mechanism
- Onset within 45–60 minutes; duration 6–12 hours
Storage & Reconstitution
Store at -20°C. Reconstitute with 2 mL bacteriostatic water → 5 mg/mL. Stable 4 weeks at 2–8°C.
Do not exceed 1 dose per 24 hours. Typical research protocol: as-needed dosing.